Independent
Tenure on this board
23.5 yrs
Meeting calendar
TECH · Annual meeting · Thursday, October 30, 2025
Bio-techne Corp
9 nominees · 4 ballot items.
Bio-Techne's 2025 proxy statements propose four management-led matters: set board size to nine; election of nine directors; advisory say-on-pay on executive compensation; and ratification of KPMG LLP as Bio-Techne's independent registered public accounting firm for fiscal year 2026.
Market cap
$11.1B
1Y TSR
+14.3%
Board grade
C-
Record date
Sep 5, 2025
Filing
DEF 14A
Meeting concluded · Oct 30, 2025
Follow how the vote landed and what changed on Bio-techne Corp’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot4
- 1
Size of the Board
ManagementBoard: FORSet the number of directors at nine.
- 2
Election of Directors
ManagementBoard: FORElect the nine director nominees identified in this Proxy Statement, each for a term of one year.
- 3
Advisory Vote on Executive Compensation
ManagementBoard: FORApprove, on an advisory basis, the compensation of our named executive officers.
- 4
Ratification of the Appointment of KPMG LLP as the Company’s Independent Registered Public Accounting Firm for Fiscal Year 2026
ManagementBoard: FORRatify the appointment of KPMG LLP as Bio-Techne’s independent registered public accounting firm for fiscal year ending June 30, 2026.
Director elections
Nominees on the ballot9
Independent
Tenure on this board
5.9 yrs
Also a director at
Adient PLC (ADNT)Phillips 66 (PSX)
Independent
Tenure on this board
1.4 yrs
Independent
Tenure on this board
17.1 yrs
Also a director at
Omniab Inc (OABI)
Independent
Tenure on this board
8.7 yrs
Not independent
Tenure on this board
2.4 yrs
Also a director at
Conmed Corp (CNMD)
Independent
Tenure on this board
2.2 yrs
Independent
Tenure on this board
8.7 yrs
Also a director at
Keros Therapeutics Inc (KROS)Dr Reddys Laboratories Ltd (RDY)
Rupert Vessey, MA, BM BCh, FRCP, DPhil
Independent
Tenure on this board
New nominee
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 6.5% | 10,179,709 | $532M |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.1% | 6,480,337 | $339M |
| 3 | FMR LLC | 4.1% | 6,353,103 | $332M |
| 4 | STATE STREET CORP | 3.7% | 5,868,396 | $307M |
| 5 | BlackRock, Inc. | 3.7% | 5,802,662 | $303M |
| 6 | MORGAN STANLEY | 3.1% | 4,802,920 | $251M |
| 7 | MAVERICK CAPITAL LTD | 3.0% | 4,739,721 | $248M |
| 8 | WELLINGTON MANAGEMENT GROUP LLP | 3.0% | 4,620,765 | $241M |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 2.9% | 4,603,459 | $240M |
| 10 | Durable Capital Partners LP | 2.8% | 4,456,017 | $233M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Bio-techne Corp’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Jazz Pharmaceuticals PLCJAZZ
Annual meeting·Jul 23, 2026·$15.1B
Amneal Pharmaceuticals IncAMRX
Special meeting·Jul 31, 2026·$5.5B
Catalyst Pharmaceuticals IncCPRX
Special meeting·Jul 8, 2026·$3.8B
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.6B
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.4B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.2B
Reference
Frequently asked questions
- When is the Bio-techne Corp 2025 annual meeting?
- Bio-techne Corp (TECH) holds its 2025 annual shareholder meeting on Thursday, October 30, 2025.
- What is the record date for the Bio-techne Corp 2025 meeting?
- The record date for the Bio-techne Corp 2025 meeting is Friday, September 5, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Bio-techne Corp's 2025 meeting?
- The board is presenting 9 director nominees at the Bio-techne Corp 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Bio-techne Corp 2025 meeting?
- Shareholders will vote on 4 proposals at the Bio-techne Corp 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.